Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated 
Asian Stocks Rally as Fed Rate Cut Bets Weigh on Dollar and Fuel Precious Metals Surge 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Volatility 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Gold and Silver Hit Record Highs as Safe-Haven Demand Surges Amid Global Uncertainty 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Every generation thinks they had it the toughest, but for Gen Z, they’re probably right 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Why have so few atrocities ever been recognised as genocide? 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice 
Silver Prices Hit Record Highs: How Silver Is Traded and Why Demand Is Surging 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
